<p>隨着假期縮短的一週開始，美國主要股指下跌，科技股領跌，貴金屬從近期高位回落。在如此波動的市場環境中，識別具有增長潛力的股票可能具有挑戰性，但也充滿回報。便士股票通常與較小或新興公司相關，繼續為願意超越傳統藍籌股選擇的投資者提供引人注目的機會。當這些股票背靠強大的財務健康和穩固的基本面時，能夠提供顯著的增長潛力。</p>
<h3>美國前 10 大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.68</td>
<td>$617.2M</td>
<td>✅ 3 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.88</td>
<td>$679.93M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8371</td>
<td>$145.28M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.30</td>
<td>$555.27M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.14</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.29</td>
<td>$563.4M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Nephros (NEPH)</td>
<td>$4.87</td>
<td>$51.75M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$1.00</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.08</td>
<td>$92.44M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國便士股票篩選器中的 339 只股票的完整列表。</p>
<p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
<h2>Vuzix (VUZI)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Vuzix Corporation 設計、製造和銷售全球範圍內的 AI 驅動智能眼鏡、波導和增強現實技術，市值為 2.6922 億美元。</p>
<p><strong>運營：</strong> 該公司的收入主要來自其視頻眼鏡產品部門，貢獻了 531 萬美元。</p>
<p><strong>市值：</strong> 2.6922 億美元</p>
<p>Vuzix Corporation 市值為 2.6922 億美元，積極尋求戰略聯盟並擴大客户基礎，以增強其在增強現實領域的地位。與 Collins Aerospace 在國防應用方面的近期合作以及與 BUNDLAR 的合作突顯了潛在的增長途徑。儘管從視頻眼鏡產品中產生了 531 萬美元的收入，Vuzix 仍處於虧損狀態，過去五年虧損不斷增加，但相對於負債保持強勁的現金狀況。公司的管理層經驗豐富，且沒有債務，儘管股價波動性較大，但預計年收入增長率為 75.45%。</p>
<ul>
<li>點擊這裏閲讀我們的資產負債表健康報告，深入瞭解 Vuzix 的表現。</li>
<li>通過查看我們的增長報告，瞭解 Vuzix 的盈利前景。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/640652d4-24b2-40b7-a422-0318e30959b3/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/640652d4-24b2-40b7-a422-0318e30959b3/chart/financial-position-analysis"/></p>
<p>截至 2025 年 12 月的 VUZI 財務狀況分析</p>
<h2>Aclaris Therapeutics (ACRS)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
<p><strong>概述：</strong> Aclaris Therapeutics, Inc. 是一家臨牀階段的生物製藥公司，專注於開發針對美國免疫炎症疾病的新型藥物候選者，市值為 3.2612 億美元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其治療部門，產生了 1376 萬美元，以及合同研究服務，貢獻了 1637 萬美元。</p>
<p><strong>市值：</strong> 3.2612 億美元</p>
<p>Aclaris Therapeutics 市值為 3.2612 億美元，正在應對波動的便士股票市場，同時專注於免疫炎症治療。儘管處於虧損狀態且虧損不斷增加，但公司無債務，保持強勁的現金狀況，短期資產為 1.006 億美元，超過負債。最近被納入納斯達克生物技術指數可能會提高投資者的關注度。收入從去年同期的 435 萬美元下降至 2025 年第三季度的 330 萬美元，但預計年收入增長率為 22.29%，在股價波動性較大和管理團隊經驗不足的情況下提供潛在的上行空間。</p>
<ul>
<li>點擊探索我們在 Aclaris Therapeutics 財務健康報告中的詳細發現。</li>
<li>通過查看我們的增長報告，獲取 Aclaris Therapeutics 的未來方向的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b035627f-e16a-442f-99a6-969783c043a7/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b035627f-e16a-442f-99a6-969783c043a7/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 12 月的 ACRS 債務與股本歷史及分析</p>
<h2>Prelude Therapeutics (PRLD)</h2>
<p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家臨牀階段的精準腫瘤學公司，致力於為服務不足的患者發現和開發新型癌症藥物，市值為 2.4225 億美元。</p>
<p><strong>運營：</strong> Prelude Therapeutics 從其生物技術（初創公司）部門產生收入，總計 1050 萬美元。</p>
<p><strong>市值：</strong> 2.4225 億美元</p>
<p>Prelude Therapeutics 市值為 2.4225 億美元，專注於精準腫瘤學，正在應對便士股票市場。儘管處於虧損狀態且股本回報率為負，但公司無債務，保持足夠的短期資產以覆蓋負債。公司最近通過私募融資籌集了 2500 萬美元，並申請了 912.5 萬美元的貨架註冊，表明其努力在當前的 7 個月現金流之外增強現金儲備。最近在主要會議上展示的臨牀前數據突顯了其 JAK2V617F 抑制劑和 mCALR 靶向療法的有希望進展，儘管股價波動性較大，但可能會增強投資者的興趣。</p>
<ul>
<li>通過我們的綜合資產負債表健康報告，深入瞭解 Prelude Therapeutics 的複雜性。</li>
<li>查看我們的增長表現報告，以獲取對 Prelude Therapeutics 未來的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 12 月 PRLD 債務與股本歷史及分析</p>
<h2>將想法轉化為行動</h2>
<ul>
<li>點擊這裏仔細查看我們 339 家美國便士股票公司的名單。</li>
<li>考慮其他策略？最新的 GPU 需要一種叫做鋱的稀土金屬，全球只有 38 家公司在探索或生產它。免費獲取名單。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>移動基礎設施用於國防和災難應對</p>
<p>下一波機器人技術不是類人型的，而是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

VUZI

PRLD

<p>隨着美國股指下跌，低價股為投資者提供了增長機會。值得注意的股票包括 Vuzix Corporation（市值 2.6922 億美元），專注於人工智能驅動的智能眼鏡，以及 Aclaris Therapeutics（市值 3.2612 億美元），這是一家開發免疫炎症疾病治療方案的生物製藥公司。Prelude Therapeutics（市值 2.4225 億美元）專注於精準腫瘤學。儘管這些公司尚未盈利，但它們保持着強勁的現金儲備，並正在探索戰略合作伙伴關係以增強增長潛力。投資者被鼓勵在市場波動中考慮這些新興股票</p>

<p>As the holiday-shortened week begins, major U.S. stock indexes have dipped, with technology shares leading the decline and precious metals retreating from recent highs. In such a fluctuating market landscape, identifying stocks with potential for growth can be challenging but rewarding. Penny stocks, often associated with smaller or emerging companies, continue to offer intriguing opportunities for investors willing to explore beyond traditional blue-chip options. These stocks can provide significant growth potential when backed by strong financial health and solid fundamentals.</p>
<div class="lb-trans"><p>隨着假期縮短的一週開始，美國主要股指下跌，科技股領跌，貴金屬從近期高位回落。在如此波動的市場環境中，識別具有增長潛力的股票可能具有挑戰性，但也充滿回報。便士股票通常與較小或新興公司相關，繼續為願意超越傳統藍籌股選擇的投資者提供引人注目的機會。當這些股票背靠強大的財務健康和穩固的基本面時，能夠提供顯著的增長潛力。</p>
</div><h3>Top 10 Penny Stocks In The United States</h3>
<div class="lb-trans"><h3>美國前 10 大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.68</td>
<td>$617.2M</td>
<td>✅ 3 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.88</td>
<td>$679.93M</td>
<td>✅ 4 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8371</td>
<td>$145.28M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.30</td>
<td>$555.27M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.14</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.29</td>
<td>$563.4M</td>
<td>✅ 5 ⚠️ 0 View Analysis &gt;</td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 View Analysis &gt;</td>
</tr>
<tr>
<td>Nephros (NEPH)</td>
<td>$4.87</td>
<td>$51.75M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$1.00</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.08</td>
<td>$92.44M</td>
<td>✅ 3 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>股價</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益與風險</strong></td>
</tr>
<tr>
<td>Dingdong (Cayman) (DDL)</td>
<td>$2.68</td>
<td>$617.2M</td>
<td>✅ 3 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Waterdrop (WDH)</td>
<td>$1.88</td>
<td>$679.93M</td>
<td>✅ 4 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>WM Technology (MAPS)</td>
<td>$0.8371</td>
<td>$145.28M</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>LexinFintech Holdings (LX)</td>
<td>$3.30</td>
<td>$555.27M</td>
<td>✅ 4 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>Tuya (TUYA)</td>
<td>$2.14</td>
<td>$1.29B</td>
<td>✅ 4 ⚠️ 1 查看分析 </td>
</tr>
<tr>
<td>CI&amp;T (CINT)</td>
<td>$4.29</td>
<td>$563.4M</td>
<td>✅ 5 ⚠️ 0 查看分析 </td>
</tr>
<tr>
<td>Golden Growers Cooperative (GGRO.U)</td>
<td>$5.00</td>
<td>$77.45M</td>
<td>✅ 2 ⚠️ 5 查看分析 </td>
</tr>
<tr>
<td>Nephros (NEPH)</td>
<td>$4.87</td>
<td>$51.75M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
<tr>
<td>BAB (BABB)</td>
<td>$1.00</td>
<td>$7.26M</td>
<td>✅ 2 ⚠️ 3 查看分析 </td>
</tr>
<tr>
<td>Lifetime Brands (LCUT)</td>
<td>$4.08</td>
<td>$92.44M</td>
<td>✅ 3 ⚠️ 2 查看分析 </td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 339 stocks from our US Penny Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國便士股票篩選器中的 339 只股票的完整列表。</p>
</div><p>Let's uncover some gems from our specialized screener.</p>
<div class="lb-trans"><p>讓我們從我們的專業篩選器中發現一些寶藏。</p>
</div><h2>Vuzix (VUZI)</h2>
<div class="lb-trans"><h2>Vuzix (VUZI)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Vuzix Corporation designs, manufactures, and markets AI-powered smart glasses, waveguides, and augmented reality technologies globally with a market cap of $269.22 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Vuzix Corporation 設計、製造和銷售全球範圍內的 AI 驅動智能眼鏡、波導和增強現實技術，市值為 2.6922 億美元。</p>
</div><p><strong>Operations:</strong> The company generates its revenue primarily from its Video Eyewear Products segment, which accounted for $5.31 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自其視頻眼鏡產品部門，貢獻了 531 萬美元。</p>
</div><p><strong>Market Cap:</strong> $269.22M</p>
<div class="lb-trans"><p><strong>市值：</strong> 2.6922 億美元</p>
</div><p>Vuzix Corporation, with a market cap of US$269.22 million, has been actively pursuing strategic alliances and expanding its client base to bolster its position in the augmented reality sector. Recent collaborations with Collins Aerospace for defense applications and partnerships like BUNDLAR highlight potential growth avenues. Despite generating US$5.31 million from Video Eyewear Products, Vuzix remains unprofitable with increasing losses over five years but maintains a strong cash position relative to liabilities. The company's management is experienced, and it has no debt, though high share price volatility persists alongside significant revenue growth forecasts of 75.45% annually.</p>
<div class="lb-trans"><p>Vuzix Corporation 市值為 2.6922 億美元，積極尋求戰略聯盟並擴大客户基礎，以增強其在增強現實領域的地位。與 Collins Aerospace 在國防應用方面的近期合作以及與 BUNDLAR 的合作突顯了潛在的增長途徑。儘管從視頻眼鏡產品中產生了 531 萬美元的收入，Vuzix 仍處於虧損狀態，過去五年虧損不斷增加，但相對於負債保持強勁的現金狀況。公司的管理層經驗豐富，且沒有債務，儘管股價波動性較大，但預計年收入增長率為 75.45%。</p>
</div><ul>
<li>Get an in-depth perspective on Vuzix's performance by reading our balance sheet health report here.</li>
<li>Understand Vuzix's earnings outlook by examining our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏閲讀我們的資產負債表健康報告，深入瞭解 Vuzix 的表現。</li>
<li>通過查看我們的增長報告，瞭解 Vuzix 的盈利前景。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/640652d4-24b2-40b7-a422-0318e30959b3/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/640652d4-24b2-40b7-a422-0318e30959b3/chart/financial-position-analysis"/></p>
<p>VUZI Financial Position Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 VUZI 財務狀況分析</p>
</div><h2>Aclaris Therapeutics (ACRS)</h2>
<div class="lb-trans"><h2>Aclaris Therapeutics (ACRS)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases in the United States, with a market cap of $326.12 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Aclaris Therapeutics, Inc. 是一家臨牀階段的生物製藥公司，專注於開發針對美國免疫炎症疾病的新型藥物候選者，市值為 3.2612 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its Therapeutics segment, generating $13.76 million, and Contract Research services, contributing $16.37 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其治療部門，產生了 1376 萬美元，以及合同研究服務，貢獻了 1637 萬美元。</p>
</div><p><strong>Market Cap:</strong> $326.12M</p>
<div class="lb-trans"><p><strong>市值：</strong> 3.2612 億美元</p>
</div><p>Aclaris Therapeutics, with a market cap of US$326.12 million, is navigating the volatile penny stock landscape while focusing on immune-inflammatory treatments. Despite being unprofitable and facing increasing losses, the company remains debt-free and maintains a strong cash position with short-term assets of US$100.6 million exceeding liabilities. Recent inclusion in the NASDAQ Biotechnology Index may enhance visibility among investors. Revenue has declined to US$3.3 million for Q3 2025 from US$4.35 million a year ago, but revenue growth is projected at 22.29% annually, providing potential upside amidst high share price volatility and an inexperienced management team.</p>
<div class="lb-trans"><p>Aclaris Therapeutics 市值為 3.2612 億美元，正在應對波動的便士股票市場，同時專注於免疫炎症治療。儘管處於虧損狀態且虧損不斷增加，但公司無債務，保持強勁的現金狀況，短期資產為 1.006 億美元，超過負債。最近被納入納斯達克生物技術指數可能會提高投資者的關注度。收入從去年同期的 435 萬美元下降至 2025 年第三季度的 330 萬美元，但預計年收入增長率為 22.29%，在股價波動性較大和管理團隊經驗不足的情況下提供潛在的上行空間。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Aclaris Therapeutics' financial health report.</li>
<li>Gain insights into Aclaris Therapeutics' future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 Aclaris Therapeutics 財務健康報告中的詳細發現。</li>
<li>通過查看我們的增長報告，獲取 Aclaris Therapeutics 的未來方向的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/b035627f-e16a-442f-99a6-969783c043a7/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/b035627f-e16a-442f-99a6-969783c043a7/chart/debt-equity-history-analysis"/></p>
<p>ACRS Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ACRS 債務與股本歷史及分析</p>
</div><h2>Prelude Therapeutics (PRLD)</h2>
<div class="lb-trans"><h2>Prelude Therapeutics (PRLD)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 財務健康評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Prelude Therapeutics Incorporated is a clinical-stage precision oncology company dedicated to discovering and developing novel cancer medicines for underserved patients, with a market cap of $242.25 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Prelude Therapeutics Incorporated 是一家臨牀階段的精準腫瘤學公司，致力於為服務不足的患者發現和開發新型癌症藥物，市值為 2.4225 億美元。</p>
</div><p><strong>Operations:</strong> Prelude Therapeutics generates revenue from its Biotechnology (Startups) segment, totaling $10.5 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> Prelude Therapeutics 從其生物技術（初創公司）部門產生收入，總計 1050 萬美元。</p>
</div><p><strong>Market Cap:</strong> $242.25M</p>
<div class="lb-trans"><p><strong>市值：</strong> 2.4225 億美元</p>
</div><p>Prelude Therapeutics, with a market cap of US$242.25 million, is navigating the penny stock arena by focusing on precision oncology. Despite being unprofitable and having a negative return on equity, it has no debt and maintains sufficient short-term assets to cover liabilities. The company recently raised US$25 million through private placement and filed a shelf registration for US$9.125 million, indicating efforts to bolster its cash runway beyond the current 7 months. Recent preclinical data presentations at major conferences highlight promising developments in their JAK2V617F inhibitors and mCALR-targeted therapies, potentially enhancing investor interest despite high share price volatility.</p>
<div class="lb-trans"><p>Prelude Therapeutics 市值為 2.4225 億美元，專注於精準腫瘤學，正在應對便士股票市場。儘管處於虧損狀態且股本回報率為負，但公司無債務，保持足夠的短期資產以覆蓋負債。公司最近通過私募融資籌集了 2500 萬美元，並申請了 912.5 萬美元的貨架註冊，表明其努力在當前的 7 個月現金流之外增強現金儲備。最近在主要會議上展示的臨牀前數據突顯了其 JAK2V617F 抑制劑和 mCALR 靶向療法的有希望進展，儘管股價波動性較大，但可能會增強投資者的興趣。</p>
</div><ul>
<li>Navigate through the intricacies of Prelude Therapeutics with our comprehensive balance sheet health report here.</li>
<li>Review our growth performance report to gain insights into Prelude Therapeutics' future.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過我們的綜合資產負債表健康報告，深入瞭解 Prelude Therapeutics 的複雜性。</li>
<li>查看我們的增長表現報告，以獲取對 Prelude Therapeutics 未來的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/a558295b-637c-4ff8-9788-f601ffb51c77/chart/debt-equity-history-analysis"/></p>
<p>PRLD Debt to Equity History and Analysis as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月 PRLD 債務與股本歷史及分析</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>將想法轉化為行動</h2>
</div><ul>
<li>Take a closer look at our US Penny Stocks list of 339 companies by clicking here.</li>
<li>Contemplating Other Strategies? The latest GPUs need a type of rare earth metal called Terbium and there are only 38 companies in the world exploring or producing it. Find the list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏仔細查看我們 339 家美國便士股票公司的名單。</li>
<li>考慮其他策略？最新的 GPU 需要一種叫做鋱的稀土金屬，全球只有 38 家公司在探索或生產它。免費獲取名單。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，內容具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移動基礎設施用於國防和災難應對</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的，而是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

3 只市值低於 4 億美元的有前景的便士股